This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q91.7 | Special Copayment Reduction: V160 | Re-certification cycle: 5 years |
| B. Synonyms | None |
| C. Adult onset | Adult onset: none — the unspecified type of Patau syndrome also presents with multiple malformations around birth, and survival to adulthood is rare. Cases with an unconfirmed karyotype are coded based on clinical diagnosis, so reclassification to Q91.4–Q91.6 after subsequent karyotype confirmation is recommended. |
| 1. History | How it was established as a subtype-unspecified code in the ICD-10 classification after the clinical description of Patau syndrome. |
| 2. Causes | One of Q91.4–Q91.6, but karyotype analysis not performed or not confirmed. Code based on clinical diagnosis. |
| 3. Genetics | Unconfirmed. Clinically diagnosed as Patau syndrome, but cytogenetic subtype unknown. Karyotype confirmation recommended. |
| 4. General epidemiology | Refer to the overall epidemiology of Patau syndrome. Some cases have only a clinical diagnosis. |
| 5. Pathophysiology | Unconfirmed subtype. Possibly one of meiotic nondisjunction, mitotic nondisjunction, or translocation. Mechanism needs to be determined. |
| 6. Symptoms | Typical clinical features of Patau syndrome. Holoprosencephaly, polydactyly, cardiac malformations, facial malformations. |
| 7. Signs | Same physical signs as Q91.4. Patau syndrome diagnosed on clinical diagnostic criteria. |
| 8. Screening | Same prenatal screening as for Patau syndrome. Rapid karyotype analysis is needed at the clinical diagnosis stage. |
| 9. Diagnosis | Based on clinical diagnosis. Subtype confirmation by karyotype analysis and reclassification to Q91.4–Q91.6 are essential. FISH, CMA. |
| 10. Treatment | Same multidisciplinary palliative care and supportive treatment as for complete Patau syndrome. |
| 11. Prognosis | Because the subtype is unconfirmed, prognosis based on the complete form applies. Provide subtype-specific prognostic information after karyotype confirmation. |
| 12. Prevention | Establish an appropriate prevention strategy after subtype confirmation. Screening of family carriers is essential for the translocation type. |
| 13. References | Patau K (1960) and 9 others. |
Patau syndrome, unspecified (Q91.7) is the code in the International Classification of Diseases, 10th Revision (ICD-10) applied when the cytogenetic subtype of trisomy 13 (meiotic nondisjunction type Q91.4, mosaic type Q91.5, translocation type Q91.6) has not been identified. In the 1960s, when Patau syndrome was first described, karyotype analysis technology was limited or difficult to access, so there were cases in which Patau syndrome was diagnosed clinically but the cytogenetic subtype could not be identified. Against this background, ICD-10 established a separate unspecified code (Q91.7).
In the modern medical setting, Q91.7 is used mainly in two situations. First, when there are typical findings strongly suggesting Patau syndrome clinically, but karyotype analysis is delayed because the patient's condition is unstable, the family refuses testing, or for technical reasons. Second, when Patau syndrome is presumptively diagnosed based on clinical findings alone in a stillborn infant or an infant who died shortly after birth. Patau syndrome can be diagnosed on clinical criteria when characteristic combined malformations such as holoprosencephaly, postaxial polydactyly, microphthalmia, cleft lip and palate, and scalp defects are present.
With the widespread adoption of karyotype analysis technology since the 1980s, the introduction of FISH in the 1990s, and advances in microarray technology since the 2000s, it has become possible to confirm the cytogenetic subtype of Patau syndrome. In advanced medical settings today, the use of the Q91.7 code is gradually decreasing. However, the Q91.7 code is still used in resource-limited settings or when confirmation of the cytogenetic subtype is difficult in emergencies.
Although Q91.7 means that Patau syndrome has been diagnosed clinically, because the subtype is unconfirmed, there are limits to recurrence risk counseling and genetic counseling for the family. In particular, unless it is confirmed that it is not the translocation type (Q91.6, about 10–15%), balanced Robertsonian translocation carriers with a risk of recurrence in the family may be missed. Therefore, when temporarily coded as Q91.7, it is clinically important to perform karyotype analysis as soon as possible to confirm the subtype and reclassify to Q91.4–Q91.6.
In Korea, too, the Q91.7 code may be used as a temporary code after the clinical diagnosis of Patau syndrome and before cytogenetic confirmation. Since Q91.4–Q91.7 are all included when applying for the rare disease Special Copayment Reduction V160, an application is possible with temporary coding, but updating the code after subsequent subtype confirmation is recommended.
Because the cytogenetic subtype of Patau syndrome, unspecified (Q91.7) is unconfirmed, in terms of cause it may be any one of Q91.4 (meiotic nondisjunction), Q91.5 (mosaic type), or Q91.6 (translocation type). In clinical practice, Q91.7 is applied when Patau syndrome has been diagnosed clinically but karyotype analysis has not been performed or the results are uncertain.
Considering the overall distribution of causes of Patau syndrome, most cases classified as Q91.7 are also presumed to be the meiotic nondisjunction type (about 80%). However, because the translocation type accounts for about 10–15%, the presence of the translocation type must be checked in all patients temporarily classified as Q91.7.
Cases due to meiotic nondisjunction: meiotic nondisjunction of chromosome 13 during oocyte or sperm formation produces aneuploid gametes leading to a 47,+13 karyotype, which become trisomic zygotes after fertilization. Advanced maternal age is the main risk factor. About 80% of all Patau syndrome arises by this mechanism.
Mosaic type due to mitotic nondisjunction: mitotic nondisjunction occurs in early development of the fertilized egg, resulting in a mosaic state in which normal cells and trisomic cells coexist. It accounts for about 5% of the total. Because the phenotype varies with the proportion of abnormal cells, clinical diagnosis may be difficult.
Translocation type due to Robertsonian translocation: arises from unbalanced segregation in a parent who is a balanced Robertsonian translocation carrier. It accounts for about 10–15% of the total. Because familial occurrence is possible, parental karyotype analysis is essential. When the Q91.7 code is used temporarily, the possibility of the translocation type must always be considered.
When using the Q91.7 code, the clinician must subsequently confirm the subtype through karyotype analysis or molecular genetic testing and update it to the appropriate code among Q91.4, Q91.5, and Q91.6. The unconfirmed subtype status should be temporary, and the final diagnosis must be clearly recorded.
In Patau syndrome, unspecified (Q91.7), the genetic details cannot be known until karyotype confirmation is performed. However, when Patau syndrome can be diagnosed clinically, all of the following cytogenetic possibilities should be kept in mind.
Complete trisomy, meiotic nondisjunction type (Q91.4): the most common case (about 80%). Karyotype 47,XX,+13 or 47,XY,+13. Parental karyotypes normal. Recurrence risk is about 1% or the age-based risk, whichever is higher. Correlated with advanced maternal age.
Mosaic type (Q91.5): accounts for about 5%. Karyotype mos 47,+13[n]/46[n]. Because the phenotype varies with the proportion of abnormal cells, in some cases Patau syndrome is not suspected on clinical diagnosis. Parental karyotypes normal. Low dependence on maternal age.
Robertsonian translocation type (Q91.6): accounts for about 10–15%. The karyotype has 46 chromosomes, but there are three copies of chromosome 13 long-arm material due to rob(13;14), etc. One parent may be a balanced Robertsonian translocation carrier. Recurrence risk may be high. Because of this possibility, confirming the presence of the translocation type by karyotype analysis is essential in all patients with Patau syndrome.
If karyotype analysis is not performed in patients temporarily classified as Q91.7, the possibility of the translocation type cannot be excluded, so only incomplete recurrence risk information is provided to the family. This may cause the patient's family to miss opportunities for prevention. Therefore, after a clinical diagnosis of Patau syndrome, karyotype analysis should be performed as soon as the clinical condition allows.
When karyotype analysis is not possible (e.g., early death, failure of tissue preservation), postmortem cytogenetic analysis using FISH or molecular genetic analysis on paraffin-embedded tissue is possible. If possible, preserving blood or tissue before death for cytogenetic analysis is recommended.
Patau syndrome, unspecified (Q91.7) is not a subtype with separate epidemiological characteristics, but a code applied to cases clinically diagnosed as Patau syndrome whose cytogenetic subtype has not been confirmed. Therefore, for the epidemiology of Q91.7, epidemiological data for Patau syndrome as a whole (Q91.4–Q91.7) should be referenced.
The overall birth frequency of Patau syndrome is about 1/5,000–1/12,000. The proportion of cases using the Q91.7 code varies by era and by the level of a country's medical care. In countries with sufficient medical resources and standardized cytogenetic testing, the proportion of Q91.7 use is low, and it may be high in the opposite setting. In the past (before the karyotype analysis era), all cases of Patau syndrome were based on clinical diagnosis, so virtually all corresponded to Q91.7.
Situations in which Q91.7 is applied in the modern medical setting: (1) In the neonatal intensive care unit, when Patau syndrome is clinically evident but specimen collection is difficult because the infant's condition is critical. (2) When the family refuses genetic testing. (3) When karyotype analysis fails for technical reasons (cell culture failure, poor specimen). (4) When a presumptive diagnosis of Patau syndrome is made in a stillborn infant based on clinical findings alone. (5) When temporary diagnostic coding is needed in an emergency.
In Korea, the Q91.7 code is rarely used in health insurance claims data, but the exact number of cases is difficult to determine from published data. It is necessary to standardize the procedure for registering Q91.7 as a temporary code in congenital anomaly registration systems and rare disease registries and updating it after karyotype analysis results.
Maternal age and other epidemiological characteristics: because Q91.7 is cytogenetically unconfirmed, the maternal age distribution for this code follows the characteristics of Patau syndrome as a whole. Since the meiotic nondisjunction type is the majority, the tendency toward advanced maternal age is reflected.
Because the cytogenetic subtype of Patau syndrome, unspecified (Q91.7) is unconfirmed, its pathophysiological mechanism is also not established. However, it is clinically important to understand the mechanisms of all three known cytogenetic subtypes of Patau syndrome and to confirm which mechanism applies.
Meiotic nondisjunction mechanism (corresponding to Q91.4): nondisjunction of chromosome 13 during oocyte or sperm formation results in a 47,+13 karyotype. Reduced oocyte cohesin and spindle–kinetochore attachment errors in advanced maternal age are involved. Maternal origin accounts for about 70–80%, making it the main mechanism.
Mitotic nondisjunction mechanism (corresponding to Q91.5): errors in the separation of chromosome 13 sister chromatids during early embryonic development of the fertilized egg produce a mosaic state in which normal cells and trisomic cells coexist. The proportion of abnormal cells is determined by the timing of occurrence.
Robertsonian translocation mechanism (corresponding to Q91.6): unbalanced segregation during meiosis in a parent who carries a Robertsonian translocation such as a balanced rob(13;14) produces offspring with excess chromosome 13 long-arm material. In carriers of a rob(13;13) centric fusion, theoretically 100% of offspring have Patau syndrome.
When temporarily classified as Q91.7, which mechanism is more likely can be estimated from clinical findings and epidemiological information (maternal age, family history, history of previous trisomic pregnancies). When it occurs with advanced maternal age, the meiotic nondisjunction type is likely, and when it occurs in young parents, the translocation or mosaic type cannot be excluded. However, because the mechanism cannot be established from clinical information alone, cytogenetic confirmation is always required.
Clinical significance of determining the mechanism: if it is the meiotic nondisjunction type, the recurrence risk is low, and age-based risk counseling is sufficient. If it is the mosaic type, the recurrence risk is low, but predicting the phenotype is difficult. If it is the translocation type, parental karyotype analysis is used to determine whether a parent is a balanced translocation carrier, and if so, the recurrence risk is high and active preventive measures (PGT-SR, prenatal diagnosis) are needed. This difference is the most important clinical reason to confirm the cytogenetic subtype quickly in the Q91.7 state.
The clinical symptoms of Patau syndrome, unspecified (Q91.7) are the same as the characteristic symptoms of Patau syndrome in general. Because Q91.7 is a code based on clinical diagnosis, patients classified as Q91.7 have the typical clinical findings of Patau syndrome.
Central nervous system malformations: holoprosencephaly (HPE) is the most characteristic finding, with the alobar type being the most common. Severe structural brain abnormalities due to holoprosencephaly are the key finding for the clinical diagnosis of Patau syndrome. Microcephaly, agenesis of the corpus callosum, and Dandy-Walker malformation may be present. In the absence of holoprosencephaly (possible mosaic type), clinical diagnosis may be difficult.
Facial malformations: midline facial malformations associated with HPE (cyclopia, proboscis, median cleft lip), microphthalmia or anophthalmia, and cleft lip and palate are characteristic. These facial malformations are findings that strongly suggest Patau syndrome clinically.
Postaxial polydactyly: extra fingers or toes on the little-finger side appear in 60–80%. This is an important point in clinically distinguishing Edwards syndrome (overlapping fingers) from Patau syndrome.
Scalp defects: localized scalp skin defects are observed in about 20–30%. This is a relatively specific finding for Patau syndrome.
Cardiovascular malformations: congenital heart malformations are present in about 80%. VSD, PDA, ASD, etc. are common.
Genitourinary malformations: renal cysts, hydronephrosis, and renal dysplasia occur in about 50%.
Respiratory problems: apneic episodes act as a main cause of death from the neonatal period.
When diagnosing Patau syndrome based on clinical findings alone, differentiation from Edwards syndrome, Miller syndrome, Smith-Opitz syndrome, and other genetic disorders associated with holoprosencephaly is needed. The combination of holoprosencephaly + postaxial polydactyly most strongly suggests Patau syndrome.
The physical signs of Patau syndrome, unspecified (Q91.7) are the same as those of complete Patau syndrome (Q91.4). Because Q91.7 is a code based on clinical diagnosis, it is applied to patients with typical physical signs of Patau syndrome.
Craniofacial signs: cyclopia (orbital fusion), proboscis, median cleft lip, and microphthalmia or anophthalmia due to holoprosencephaly are characteristic. Even in the absence of HPE, microphthalmia, cleft lip and palate, low-set ears, and microcephaly suggest Patau syndrome.
Scalp defects: localized skin defects of the scalp are observed in about 20–30%.
Limb signs: postaxial polydactyly is observed in 60–80%, and this is the most important physical sign for clinically distinguishing Patau syndrome from Edwards syndrome. It contrasts with the overlapping fingers of Edwards syndrome. Clubfoot may appear.
Cardiac signs: heart murmur, cyanosis, and signs of heart failure may appear.
Neurological signs: hypotonia, apneic episodes, and seizures are common.
Clinical diagnostic criteria: the clinical diagnosis of Patau syndrome is made from a combination of the following findings: (1) Holoprosencephaly (especially alobar or semilobar). (2) Postaxial polydactyly or syndactyly. (3) Microphthalmia or anophthalmia. (4) Scalp defect (cutis aplasia). (5) Cleft lip and palate (especially median cleft lip). (6) Cardiac malformation. (7) Renal cysts. A clinical diagnosis of Patau syndrome can be made when several of these findings are present, but confirmation is by cytogenetic testing.
Clinical points for differentiating Patau syndrome from Edwards syndrome: holoprosencephaly and postaxial polydactyly, which are characteristic of Patau syndrome, are rare in Edwards syndrome. Conversely, the characteristic overlapping fingers, short sternum, and pes cavus of Edwards syndrome are not prominent in Patau syndrome.
Screening for Patau syndrome, unspecified (Q91.7) is the same as the screening strategy for Patau syndrome as a whole (Q91.4–Q91.7). Because the Q91.7 code is mainly applied to postnatal clinical diagnosis, both prenatal screening and postnatal diagnosis are discussed.
Prenatal screening: maternal serum screening (MSS), NIPT (cfDNA), and prenatal ultrasound are the main methods of prenatal screening for Patau syndrome. NIPT shows high performance for trisomy 13, with a sensitivity of 98–99%. When holoprosencephaly, polydactyly, microphthalmia, cardiac malformations, or renal cysts are found on prenatal ultrasound, chromosomal abnormalities including Patau syndrome should be strongly suspected. When Patau syndrome is suspected prenatally, karyotype analysis and subtype confirmation are performed through invasive testing, so use of the Q91.7 code is rare.
Postnatal diagnostic pathway: as soon as Patau syndrome is clinically suspected after birth, peripheral blood karyotype analysis is requested. Q91.7 is used temporarily while awaiting the karyotype results. Rapid karyotype analysis (generally 5–10 business days) is available, and in urgent cases preliminary results can be obtained within 48–72 hours by FISH. If FISH results confirm trisomy 13, the case is reclassified as Q91.4, Q91.5, or Q91.6 and the coding is updated.
Interim management in the Q91.7 state: when temporarily coded as Q91.7, clinical management of Patau syndrome (palliative care, evaluation of cardiac malformations, family support) proceeds while awaiting karyotype results. After the karyotype results are obtained, the subtype is confirmed and, if necessary, parental karyotype analysis is carried out immediately. If confirmed as the translocation type, extended family screening is recommended.
The diagnosis of Patau syndrome, unspecified (Q91.7) is a provisional diagnosis based on clinical findings, and cytogenetic testing is always required for final confirmation.
Clinical diagnostic criteria: Patau syndrome is diagnosed clinically by a combination of characteristic findings such as holoprosencephaly, postaxial polydactyly, microphthalmia, scalp defects, cardiac malformations, and renal cysts. This clinical diagnosis is provisional pending cytogenetic confirmation.
Karyotype analysis (G-banding): standard G-banded karyotype analysis is performed on peripheral blood lymphocytes. It can distinguish the complete type (47,+13), mosaic type (mos 47,+13/46), and translocation type (46 but with a rob translocation). The case is reclassified as Q91.4–Q91.6 according to the karyotype results.
FISH: rapid preliminary results are obtained with a chromosome 13-specific probe. Among cytogenetic methods, it allows the fastest provisional confirmation in the Q91.7 state. The translocation type cannot be fully characterized by FISH alone, so karyotype analysis is needed.
Chromosomal microarray (CMA): detects additional genomic imbalances along with confirming trisomy. In the mosaic type, it may be missed by CMA if the proportion of abnormal cells is low.
Parental karyotype analysis: when the translocation type is confirmed on karyotype analysis, parental karyotype analysis is performed immediately. This is the starting point for family recurrence risk counseling. Parental karyotype confirmation is recommended even when the complete type is confirmed (to confirm sporadic occurrence).
Special situations in which only clinical diagnosis is possible: blood sampling may be difficult in cases of death shortly after birth or stillbirth. In such cases, FISH or molecular genetic analysis is attempted on a skin biopsy (skin fibroblast culture), placental tissue, or paraffin-embedded tissue. The family is advised to make every effort to confirm the karyotype for recurrence risk counseling.
Treatment of Patau syndrome, unspecified (Q91.7) follows the treatment principles of the complete type (Q91.4) from the time Patau syndrome is clinically confirmed. Clinical management begins without delay even while the cytogenetic subtype is unconfirmed.
Neonatal intensive care and palliative care: as soon as a clinical diagnosis of Patau syndrome is made, a multidisciplinary team is formed and treatment goals are discussed with the family. Apnea management, respiratory support, seizure control, and nutritional support are prioritized. The poor prognosis of Patau syndrome is explained honestly to the family, and palliative care options are discussed together.
Treatment of cardiac malformations: whether to perform surgery for cardiac malformations is decided jointly by the multidisciplinary team and the family. Treatment intensity can be reassessed in light of the results of cytogenetic subtype confirmation. If confirmed as the mosaic type, more active treatment than for the complete type may be considered.
Seizure control: neonatal seizures are controlled with anticonvulsants (phenobarbital, levetiracetam).
Nutritional support: nutrition is provided by tube feeding.
Proceeding with cytogenetic testing and family counseling: even in the Q91.7 state, cytogenetic testing is carried out as quickly as possible. As soon as karyotype results are available, the family is informed of the subtype along with the recurrence risk and the need for parental karyotype analysis (especially for the translocation type). If confirmed as the translocation type, parental karyotype analysis and extended family screening are carried out immediately.
Palliative care and family support: the palliative care team and social workers work together so that the family can receive appropriate emotional, social, and spiritual support during the end-of-life process of an infant with Patau syndrome. Even after death, ongoing support is provided to the family through genetic counseling follow-up visits.
The clinical prognosis of Patau syndrome, unspecified (Q91.7) is based on the prognosis of complete Patau syndrome (Q91.4) until the cytogenetic subtype is confirmed. In the complete type, the median survival is about 7–10 days, and the 1-year survival rate is about 5–10%, which is very poor.
Once the cytogenetic subtype is confirmed, subtype-specific prognostic information is provided to the family. If it is the complete type (Q91.4), the complete-type prognosis applies; if it is the mosaic type (Q91.5), the possibility of a better prognosis depending on the proportion of abnormal cells is explained; if it is the translocation type (Q91.6), it is explained that the infant's prognosis is the same as the complete type, but that managing the family's recurrence risk is an additional prognosis-related task.
The severity of clinical findings determines individual prognosis. The severity of holoprosencephaly (alobar is the poorest), the type and severity of cardiac malformations, the presence of renal malformations, and the degree of respiratory failure affect survival time and clinical course.
When counseling the family about prognosis in the Q91.7 state, explain that there is uncertainty because the cytogenetic subtype has not yet been confirmed, and make clear that more specific prognostic and recurrence risk information will be provided after subtype confirmation. In particular, because recurrence risk counseling without excluding the possibility of the translocation type is incomplete, the clinical importance of subtype confirmation is fully explained to the family.
Genetic counseling after death: even after the infant has died, the karyotype results are explained through genetic counseling follow-up visits for the parents, and plans for future pregnancies are discussed together. When the translocation type is confirmed, referral for karyotype analysis of the parents and family members must be carried out.
The key to the prevention strategy for Patau syndrome, unspecified (Q91.7) is to establish an appropriate subtype-specific prevention strategy after confirming the cytogenetic subtype.
Importance of confirming the cytogenetic subtype: a prevention strategy cannot be fully established in the Q91.7 state. Confirming the cytogenetic subtype is the first step in the prevention strategy. If confirmed as the translocation type (Q91.6), recurrence can be prevented through parental karyotype analysis and carrier screening, whereas if it is the complete type (Q91.4), counseling that the recurrence risk is low is sufficient.
When the meiotic nondisjunction type (Q91.4) is confirmed: recurrence risk is about 1% or the age-based risk, whichever is higher. Awareness of advanced maternal age; NIPT or invasive prenatal diagnosis recommended in the next pregnancy. Prevention through PGT-A is also possible.
When the mosaic type (Q91.5) is confirmed: low recurrence risk (similar to the meiotic nondisjunction type). Prenatal diagnosis recommended in the next pregnancy. Explain the phenotypic variability and prognostic uncertainty of the mosaic type.
When the translocation type (Q91.6) is confirmed: parental karyotype analysis is essential. If a balanced Robertsonian translocation carrier is identified, active recurrence prevention with PGT-SR or prenatal diagnosis. Identify all carrier family members through extended family screening and provide genetic counseling. For carriers of a rob(13;13) centric fusion, explain that normal offspring are not possible through natural conception and offer PGT-SR.
Prenatal screening programs: as a population-level approach to preventing Patau syndrome, prenatal screening of pregnant women (NIPT, serum screening, ultrasound) is optimized. Active prenatal screening is recommended for women of advanced maternal age. This supports early detection of Patau syndrome and informed decision-making by parents.